Hoc Analysis News Today

The post-hoc analysis of the phase 3 ENHANCE study provides the first published evidence of a correlation between decreases in IL-31, bile acids, and pruritus symptoms in PBC following treatment with an investigational agent.

Incyte today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology Annual Meeting held... | May 25, 2023

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from across its oncology portfolio will be presented at the upcoming 2023 American Society of Clinical Oncology (ASCO) Annual

How to determine the TOC in inhomogeneous waste materials by the direct method using the multi N/C 2100S duo.

Late-Breaking Presentation on the Phase 3 LEAP-002 Study Investigating the Lenvatinib plus Pembrolizumab Combination Versus Lenvatinib Monotherapy in Patients With Unresectable Hepatocellular Carcinoma

This randomized clinical trial assesses whether high-flow nasal cannula therapy is noninferior to continuous positive airway pressure for time to liberation fro

This randomized trial tested whether intraoperative handovers of care from clinician to another compared with no handover after surgery affected a composite of

This randomized clinical trial assesses the effect of treatment with an antiplatelet agent vs no antiplatelet therapy on days alive and free of intensive care u

This randomized trial compares the effects of ivermectin vs placebo on time to symptom resolution within 21 days among patients with mild COVID-19.

Data from six abstracts advancing cannabidiol (CBD) research to be presented, including two abstracts which highlight results from a U.S. caregiver survey that provides insight on real-world